David Lebowitz
Stock Analyst at Citigroup
(4.30)
# 340
Out of 5,179 analysts
119
Total ratings
59.77%
Success rate
13.34%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $72.15 | +16.42% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $62.50 | +34.40% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $30.30 | +58.42% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $11.08 | +80.51% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $216.95 | +33.67% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $90.30 | +14.06% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $32.52 | +16.85% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $36.10 | -39.06% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $69.70 | -3.87% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $41.53 | +34.84% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $12.37 | -19.16% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.17 | +28.21% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $66.13 | -31.95% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $88.44 | -23.11% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $510.68 | -25.20% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $54.14 | +77.32% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $4.96 | +141.94% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $317.36 | -48.32% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $21.22 | +83.79% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $23.49 | -10.60% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $5.48 | +7,290.51% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.06 | +357.52% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $72.15
Upside: +16.42%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $62.50
Upside: +34.40%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $30.30
Upside: +58.42%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $11.08
Upside: +80.51%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $216.95
Upside: +33.67%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $90.30
Upside: +14.06%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $32.52
Upside: +16.85%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $36.10
Upside: -39.06%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $69.70
Upside: -3.87%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $41.53
Upside: +34.84%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $12.37
Upside: -19.16%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.17
Upside: +28.21%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $66.13
Upside: -31.95%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $88.44
Upside: -23.11%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $510.68
Upside: -25.20%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $54.14
Upside: +77.32%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $4.96
Upside: +141.94%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $317.36
Upside: -48.32%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $21.22
Upside: +83.79%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $23.49
Upside: -10.60%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $5.48
Upside: +7,290.51%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.06
Upside: +357.52%